RXRX Stock Price History and Quote Analysis Insights for Investors
Recursion Pharmaceuticals, Inc.
Stock Price Today
Recursion Pharmaceuticals, Inc. (RXRX) stock declined over -0.43%, trading at $6.95 on NASDAQ, down from the previous close of $6.98. The stock opened at $7.11, fluctuating between $6.75 and $7.14 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Company Information
| Employees | 500 |
| Beta | 0.8 |
| Sales or Revenue | $44.58M |
| 5Y Sales Change% | 19.78% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) stock price is $6.95 in the last trading session. During the trading session, RXRX stock reached the peak price of $7.14 while $6.75 was the lowest point it dropped to. The percentage change in RXRX stock occurred in the recent session was -0.43% while the dollar amount for the price change in RXRX stock was -$0.03.
The NASDAQ listed RXRX is part of Biotechnology industry that operates in the broader Healthcare sector. Recursion Pharmaceuticals, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Ryan Kelly
Managing Director
Dr. Michael Secora Ph.D.
Chief Financial Officer
Ms. Tina Marriott Larson
Chief Operating Officer & Pres
Ms. Louisa Daniels J.D., M.B.A.
Chief Legal Officer & Gen. Counsel
Kevin Leggat
Vice President of Fin. & Accounting
Dr. Blake C. Borgeson Ph.D.
Co-Founder & Director
Dr. Christopher C. Gibson Ph.D.
Co-Founder, Chief Executive Officer & Director
Mr. Benjamin Mabey M.S.
Chief Technology Officer
Dr. Shafique Virani M.D.
Chief Corporation Devel. Officer
Mr. Jared Allenbach
Senior Director of Investor Relations
Ms. Heather Kirkby M.B.A.
Chief People Officer
RXRX's closing price is 24.11% higher than its 52-week low of $5.60 where as its distance from 52-week high of $15.74 is -55.84%.
Number of RXRX employees currently stands at 500.
Official Website of RXRX is: https://www.recursion.com
RXRX could be contacted at phone 385 269 0203 and can also be accessed through its website. RXRX operates from 41 South Rio Grande Street, Salt Lake City, UT 84101, United States.
RXRX stock volume for the day was 9.77M shares. The average number of RXRX shares traded daily for last 3 months was 8.15M.
The market value of RXRX currently stands at $2.65B with its latest stock price at $6.95 and 381.74M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2024 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com